Solving Pharma's Data Silo Problem: Why A Linkable Data Infrastructure Is Good For Biopharma And Good For Patients

Each year, pharmaceutical companies spend billions of dollars developing therapies that can improve patient outcomes. Much of that investment goes towards the generation and procurement of data: designing carefully controlled clinical trials; buying data to understand the market and generate real-world evidence; and managing hundreds of researchers, analysts and consultants to make sense of it.

Despite investing heavily in data, pharma companies are limited by the basic problem of not being able to connect the data they’ve amassed.

Each data subscription and clinical trial provides a window of insight, but they all remain siloed. Without connecting those silos, pharma companies are unable to get a holistic view of individual patients or a more complete view of the patient population.

This problem plagues everyone from the smallest biotech startup to the largest Fortune 100 companies — and for decades, there hasn’t been a solution.

Today, leading pharmaceutical companies are connecting their siloed data and establishing a linkable data infrastructure. With the right infrastructure, both clinical and commercial leaders can extract more value from their data, run more successful clinical programs, and address patients’ unmet needs sooner.